TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB91682

Peptide_Name

HAL-1/29 HAL-1

Activity

Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity

Activity_category_statistics

Anti-infective peptides Cancer-related peptides Toxicity and safety peptides

Database_Source

AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF AFP-GFuse Antifungipept CAFPdb APD_complete APD_hemolytic Hemolytic2 PD_Hemolysis ToxinPred 3.0

Sequence_Type

standard

Has_Modification No

Description A 12-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

GMWSKILGHLIR-NH2

FASTA

>TPDB91682|Antibacterial;Anticancer;Antifungal;Antiparasitic;Antiviral;Hemolysis;Toxicity|length=12
GMWSKILGHLIR-NH2

Formula C65H107N19O14S1

Absent Amino Acids ANDCEQFPTYV

Common Amino Acids GIL

Mass 1410.74

PI 11.49

Basic Residues 3

Acidic Residues 0

Hydrophobic Residues 6

Net Charge +2

Boman Index -0.91

Hydrophobicity 0.367

Aliphatic Index 130.00

Half Life

Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour

Extinction Coefficient Cystines 5500

Absorbance 280nm 389.87

Polar Residues 1

number

0

A

1

R

0

N

0

D

0

C

0

E

0

Q

2

G

1

H

2

I

2

L

1

K

1

M

0

F

0

P

1

S

0

T

1

W

0

Y

0

V

Amino Acid Distribution

A: 0 R: 1 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 2 H: 1 I: 2 L: 2 K: 1 M: 1 F: 0 P: 0 S: 1 T: 0 W: 1 Y: 0 V: 0

Length

12

Formula

C65H107N19O14S1

Mass

1410.74

PI

11.49

Net Charge

+2

Boman Index

-0.91

Hydrophobicity

0.367

C_terminal_Modification

Amidation

Chirality

L

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Antimicrobial and Antifungal

Origin

Halictines and their analogs

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 11±2 µM

Detail Source Activity Anticancer

Activity Measurement 11

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 > 100 µM

Detail Source Activity Anticancer

Activity Measurement 100 µM

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 3 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 44±8 µM

Detail Source Activity Anticancer

Activity Measurement 44

Target

Cancer Type Colon Cancer

Cell Line SW

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 4 Activity

Activity

Activity Raw

Not tested

Detail Source Activity Anticancer

Target

Cancer Type Colon Cancer

Cell Line SW

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 5 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 49±9 µM

Detail Source Activity Anticancer

Activity Measurement 49

Target

Cancer Type Leukemia Cancer

Cell Line CCRF-CEM

Tissue Affected Blood

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 6 Activity

Activity

Activity Raw

Not tested

Detail Source Activity Anticancer

Target

Cancer Type Leukemia Cancer

Cell Line CCRF-CEM

Tissue Affected Blood

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012